Delphi Diagnostics Overview
- Year Founded
-
2016
- Status
-
Private
- Employees
-
10
- Latest Deal Type
-
Early Stage VC
- Investors
-
3
Delphi Diagnostics General Information
Description
Operator of a biotechnology company intended to develop the prognosis and prediction of breast cancer treatment. The company offers the endocrine activity index (EAI) test, which measures endocrine activity and is an innovative diagnostic that provides new information that can help optimize treatment decisions and avoid non-beneficial treatments, enabling breast cancer patients to access personalized treatment options and opening new pathways for more effective care.
Contact Information
Website
www.delphi-diagnostics.comCorporate Office
- C/o Tri Nguyen Law Office PC
- 1220 Blalock Road, Suite 300
- Houston, TX 77055
- United States
Corporate Office
- C/o Tri Nguyen Law Office PC
- 1220 Blalock Road, Suite 300
- Houston, TX 77055
- United States
Delphi Diagnostics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Early Stage VC | Completed | Generating Revenue | ||||
| 3. Later Stage VC | 14-Jun-2021 | Cancelled | Generating Revenue | |||
| 2. Accelerator/Incubator | 19-Mar-2018 | $470K | Completed | Generating Revenue | ||
| 1. Angel (individual) | 26-Jan-2017 | $470K | $470K | Completed | Generating Revenue |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Delphi Diagnostics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Delphi Diagnostics Patents
Delphi Diagnostics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20260078449-A1 | Methods and reagents for determining distance recurrence and overall survival in subjects afflicted with breast cancer | Pending | 13-Sep-2024 |
Delphi Diagnostics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Delphi Diagnostics Investors (3)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| ACC Bioscience Incubator | Accelerator/Incubator | |||
| Convergence Ventures (Houston) | Venture Capital | Minority | ||
| DigitalDx Ventures | Venture Capital | Minority |
Delphi Diagnostics FAQs
-
When was Delphi Diagnostics founded?
Delphi Diagnostics was founded in 2016.
-
Where is Delphi Diagnostics headquartered?
Delphi Diagnostics is headquartered in Houston, TX.
-
What is the size of Delphi Diagnostics?
Delphi Diagnostics has 10 total employees.
-
What industry is Delphi Diagnostics in?
Delphi Diagnostics’s primary industry is Biotechnology.
-
Is Delphi Diagnostics a private or public company?
Delphi Diagnostics is a Private company.
-
What is Delphi Diagnostics’s current revenue?
The current revenue for Delphi Diagnostics is .
-
How much funding has Delphi Diagnostics raised over time?
Delphi Diagnostics has raised $470K.
-
Who are Delphi Diagnostics’s investors?
ACC Bioscience Incubator, Convergence Ventures (Houston), and DigitalDx Ventures have invested in Delphi Diagnostics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
